Elucidation of the role of KIT and PDGFRA in the pathogenesis of GIST led to the use of the tyrosine kinase inhibitor imatinib (Gleevec), which is specific for these kinases, in this disease state. Here, KIT is linked to gastrointestinal stromal tumor.